T-cell acute lymphoblastic leukaemia (T-ALL) is a haematological malignancy with a dismal overall prognosis, including a relapse rate of up to 25%, mainly because of the lack of non-cytotoxic targeted therapy options. Drugs that target the function of key epigenetic factors have been approved in the context of haematopoietic disorders 1 , and mutations that affect chromatin modulators in a variety of leukaemias have recently been identified 2,3 ; however, 'epigenetic' drugs are not currently used for T-ALL treatment. Recently, we described that the polycomb repressive complex 2 (PRC2) has a tumour-suppressor role in T-ALL 4 . Here we delineated the role of the histone 3 lysine 27 (H3K27) demethylases JMJD3 and UTX in T-ALL. We show that JMJD3 is essential for the initiation and maintenance of T-ALL, as it controls important oncogenic gene targets by modulating H3K27 methylation. By contrast, we found that UTX functions as a tumour suppressor and is frequently genetically inactivated in T-ALL. Moreover, we demonstrated that the small molecule inhibitor GSKJ4 (ref. 5) affects T-ALL growth, by targeting JMJD3 activity. These findings show that two proteins with a similar enzymatic function can have opposing roles in the context of the same disease, paving the way for treating haematopoietic malignancies with a new category of epigenetic inhibitors.
T-cell acute lymphoblastic leukaemia (T-ALL) is a haematological malignancy with a dismal overall prognosis, including a relapse rate of up to 25%, mainly because of the lack of non-cytotoxic targeted therapy options. Drugs that target the function of key epigenetic factors have been approved in the context of haematopoietic disorders 1 , and mutations that affect chromatin modulators in a variety of leukaemias have recently been identified 2,3 ; however, 'epigenetic' drugs are not currently used for T-ALL treatment. Recently, we described that the polycomb repressive complex 2 (PRC2) has a tumour-suppressor role in T-ALL 4 . Here we delineated the role of the histone 3 lysine 27 (H3K27) demethylases JMJD3 and UTX in T-ALL. We show that JMJD3 is essential for the initiation and maintenance of T-ALL, as it controls important oncogenic gene targets by modulating H3K27 methylation. By contrast, we found that UTX functions as a tumour suppressor and is frequently genetically inactivated in T-ALL. Moreover, we demonstrated that the small molecule inhibitor GSKJ4 (ref. 5) affects T-ALL growth, by targeting JMJD3 activity. These findings show that two proteins with a similar enzymatic function can have opposing roles in the context of the same disease, paving the way for treating haematopoietic malignancies with a new category of epigenetic inhibitors.
In recent studies, we and other researchers have revealed that PRC2 has a key tumour-suppressor function, catalysing the methylation of H3K27 (refs 2, 4, 6) . Since net H3K27me3 levels are dictated by the balance between histone methylation and active histone demethylation, we hypothesized that the removal of methyl groups from H3K27 is also an important process in T-ALL progression. We therefore investigated the possible roles of H3K27 demethylases in T-ALL (see Supplementary Notes for an extended introduction). Ubiquitously transcribed tetratricopeptide repeat X-linked protein (UTX) 7, 8 (also known as KDM6A) is a ubiquitously expressed protein that controls the basal levels of H3 K27me3 and the induction of ectoderm and mesoderm differentiation 9, 10 and is essential for somatic cell reprogramming 11 . Jumonji D3 (JMJD3) 7, 8 (also known as KDM6B) is induced upon inflammation 12 or exposure to viral and oncogenic stimuli 13, 14 , and it controls neuronal and epidermal differentiation 15, 16 and inhibits reprogramming 17 . UTX is a tumour suppressor in several solid tumours 3, [18] [19] [20] [21] . However, the roles of these two demethylases as direct modulators of the oncogenic state are largely uncharacterized 13, 14 .
We have generated and studied NOTCH1-induced T-ALL animal models 4 (Fig. 1a ), because activating mutations of NOTCH1 are a defining feature of T-ALL 22 . Jmjd3 messenger RNA and protein expression levels were significantly higher in leukaemic cells than in untransformed CD4 1 CD8 1 (double positive) control T cells, which exhibit low levels of active NOTCH1, whereas Utx (and Ezh2) 4 expression did not change significantly (Fig. 1b, c and Supplementary Table 1 ) upon transformation. It has previously been shown that the transcription factor nuclear factor-kB (NF-kB) controls JMJD3 expression during inflammation 12 and that NOTCH1 induces the NF-kB pathway in T-ALL 23 . Here we showed increased expression of the p65 subunit (also known as RELA) of NF-kB and its-but not NOTCH1-binding to Jmjd3 control elements in mouse T-ALL cells (Extended Data Fig. 1a, b ). Modulation of the levels of intracellular NOTCH1 or the activity of the NF-kB pathway significantly decreased the amount of NF-kB bound to the Jmjd3 elements, as well as Jmjd3 mRNA expression (Extended Data Fig. 1b-f ). We then probed for JMJD3 binding to specific oncogenic loci, which has previously been shown to be important in T-ALL 4 . We found that JMJD3 binding was highly enriched on the Hes1 promoter ( Fig. 1d, left) , and this binding depended on the activation of the NOTCH1 pathway and negatively correlated with the H3K27me3 levels (Extended Data Fig. 1g, h) .
Analyses of human leukaemia cases 2, [24] [25] [26] have shown that JMJD3 is more highly expressed in T-ALL cells than in normal T-cell progenitors 24 or in other types of leukaemia 25, 26 , which is similar to the expression of the classic NOTCH1 target HES1 (Fig. 1e ). Genes that are co-expressed with JMJD3 in human primary samples were found to exhibit loss of H3K27me3 during leukaemia progression (Extended Data Fig. 1i ), suggesting a connection between the expression of JMJD3 and the H3K27 me3 levels on specific targets.
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) studies in human T-ALL cells (the cell line CUTTL1) showed that JMJD3 was bound to important NOTCH1 targets with oncogenic functions (such as HEY1, NRARP and HES1) ( Fig. 1f ). There was a significant co-occupancy of JMJD3 with NOTCH1 (ref. 27) (33% of the top JMJD3 peaks were occupied by NOTCH1, a 6.9-fold enrichment over control, P , 13 10 23 ), the NOTCH1 partner RBP-Jk and the activating mark H3K4me3 (ref. 27) (Extended Data Fig. 1j ). The majority of JMJD3 binding sites were localized around the transcription start sites (TSSs) of genes (Extended Data Fig. 1k ) in a fashion similar to NOTCH1 binding sites 27 . These results suggest a key role for JMJD3 in oncogenic programs in T-ALL, through interaction with NOTCH1. Protein immunoprecipitation studies in 293T cells (human embryonic kidney cells), as well as in mouse T-ALL cell lines, showed that JMJD3 is part of the NOTCH1 transcriptional complex, as it interacts directly with NOTCH1 and MAML1 (Extended Data Fig. 2a -c). By contrast, there was no NOTCH1 interaction with EZH2 or UTX. As JMJD3 has been shown to be a member of MLL complexes 12 , we tested whether JMJD3 interacted with WDR5, a key subunit of the MLL complex. We found that JMJD3 interacted with WDR5 (Extended Data Fig. 2b ), suggesting a potential NOTCH1-JMJD3-MLL complex on target promoters.
To clarify the role of JMJD3 and UTX in the maintenance of leukaemia, we performed genomic knockdown of JMJD3 in human T-ALL cells using two short hairpin RNAs (shRNAs) ( Fig. 2a, b and Extended Data Fig. 2d ). Treatment with shJMJD3 but not shUTX affected the viability of leukaemic cells, as shown in loss of representation studies and apoptosis assays, and this finding is in contrast to the viability of myeloid leukaemia lines used as controls ( Fig. 2c and Extended Data Fig. 2e , f). The expression of NOTCH1 targets was negatively affected by shJMJD3, The data shown are representative of three independent studies. FPKM, fragments per kilobase of transcript per million fragments mapped. e, In vivo growth of P12 T-ALL cells in intravenous xenograft studies upon genomic ablation of JMJD3 (left) and with a Renilla control (centre). One million P12 cells were injected into each of seven animals. Sublethally irradiated NRG (immunocompromised) mice were used as recipients, and transplanted leukaemic cell growth was compared with the baseline (day 0). Day 0 was set as the first day when substantially detectable luciferase intensity was measured. The last day of the experiment was the day that either the luciferase intensity reached saturation or the mice were killed for humane reasons. Horizontal bars, means.
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and this was accompanied by loss of JMJD3 and gain of H3K27me3 on their promoters (Extended Data Fig. 3a-e ). Genome-wide expression analysis showed that more transcripts were significantly downregulated by shJMJD3 treatment than were upregulated (749 protein-coding genes versus 297; Fig. 2d , top, and Extended Data Fig. 3f ), in agreement with the role of JMJD3 as a transcriptional activator. The downregulated genes were found to be significantly enriched in genes that gained H3K27me3 on their promoters (Fig. 2d , bottom; P 5 1.02 3 10 27 ). The shUTXdownregulated and shUTX-upregulated gene signatures were reversed in terms of the gene numbers (46 downregulated and 189 upregulated protein-coding genes, compared with both shRenilla (control) and shJMJD3). Intriguingly, JMJD3 expression itself was significantly upregulated upon UTX silencing (Extended Data Fig. 3a ). Well-characterized NOTCH1 targets, as well as genes in the NF-kB pathway were downregulated as part of the JMJD3 signature ( Fig. 2d , top, and Extended Data Fig. 3g ). These findings were confirmed using additional human T-ALL cell lines with high levels of oncogenic NOTCH1 activity 22 (Extended Data Fig. 3h , i). Subcutaneous or intravenous xenograft models of T-ALL cell lines (CUTLL1, CEM and P12) treated with either of the two shRNAs against JMJD3 (shJMJD3A and shJMJD3B) and transplanted into immunocompromised mice (NRG mice; NOD Rag1 2/2 Il2rg 2/2 ) showed a significant growth disadvantage compared with shRenilla-treated cell lines ( Fig. 2e and Extended Data Fig. 4a-f ). Interestingly, silencing of UTX led to enhanced proliferation in many cases, suggesting a possible tumour-suppressor function in vivo (Extended Data Fig. 4g ).
To examine the potential roles of UTX and JMJD3 in the induction of T-ALL, we performed bone marrow transplantation experiments using haematopoietic stem cells from Utx and Jmjd3 germline knockout mice. Although female Utx 2/2 mice die at E9.5 because of defects in mesoderm development, a small fraction of male Utx 2/Y mice survive to adulthood as a result of compensation by UTY 28 . Despite T-cell development being largely unaffected (Extended Data Fig. 5a, b) , T-ALL kinetics were significantly faster on the Utx 2/Y background, as determined by leukaemic burden quantification in the peripheral blood and infiltration of the spleen (data not shown) and liver ( Fig. 3a -c and Extended Data Fig. 5c-e ). Moreover, mice succumbed to the disease with a significantly shorter latency in the absence of Utx than in the Utx 1/Y and Utx 1/1 genotypes ( Fig. 3d and Extended Data Fig. 5f-h) . These experiments provide the first in vivo analysis of the tumour-suppressor role of UTX in any tumour type.
To delineate the potential mechanism underlying UTX action, we analysed the gene expression of sorted leukaemic blasts from the spleen or bone marrow of wild-type (Utx 1/Y /Utx 1/1 ) or knockout (Utx 2/Y ) mice ( Fig. 3e ). This analysis showed that UTX positively controls important tumour-suppressor genes, such as retinoblastoma binding protein 6 (Rbbp6), the inhibitor of NOTCH1 pathway activity Fbxw7 and the PRC2 member Suz12; by contrast, genes with an oncogenic role in T-ALL, including Jmjd3, were upregulated ( Fig. 3e and Extended Data Fig. 5i ). These studies strongly suggested that UTX might act as a tumour suppressor in human T-ALL. We thus screened a panel of primary paediatric T-ALL samples 2 for genetic alterations of the UTX locus. Analysis 
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of primary human samples of paediatric T-ALL using single nucleotide polymorphism (SNP) arrays identified two patients with focal deletions of the UTX locus ( Fig. 3f ). Further targeted sequencing in paediatric and adult T-ALL led to the identification of six more patient cases with UTX mutations (Fig. 3g , Extended Data Fig. 5j , k and Supplementary  Table 2 ), including in-frame deletions, missense (Ile598Val) mutations and frameshift alterations. Analysis of bone marrow remission genomic DNA confirmed the somatic origin of the UTX splice site mutation (Extended Data Fig. 5k ). Seven out of the eight alterations belonged to male patients, further underlining that the roles of UTX and UTY do not seem to be interchangeable. These genetic alterations are predicted to have an inactivating role 20, 21 and provide further evidence that UTX is a tumour suppressor in T-ALL. Indeed, overexpression of UTX using a doxycycline-inducible lentiviral system in T-ALL cell lines (Extended Data Fig. 5l ) led to suppression of tumour growth and a significant increase in apoptosis (Extended Data Fig. 5m , n). Jmjd3 2/2 mice 29 lack the catalytic domain of the JMJD3 protein (Extended Data Fig. 6a , b) and die perinatally 29 . Haematopoiesis and T-cell development were largely unaffected by the absence of JMJD3 (Extended Data Fig. 6c-h) . Genetic ablation of Jmjd3 in T-ALL led to fewer leukaemic blasts in the peripheral blood, significantly reduced leukaemic cell infiltration of the spleen and liver and improved survival rates in the recipients (Extended Data Fig. 7a-f ), consistent with Jmjd3 having an oncogenic role. These striking phenotypes supported our previous in vitro and in vivo findings and led us to further explore the therapeutic potential of targeting JMJD3 activity in T-ALL.
We next tested whether the small molecule GSKJ4 (ref. 5) , which is directed against JMJD3 and UTX (half-maximum inhibitory concentration (IC 50 ) as determined by matrix-assisted laser desorption mass spectroscopy, JMJD3, 18 mM; UTX 56 mM; ref. 5), affects maintenance of the disease. We used GSKJ4 at the IC 50 determined for T-ALL cells (2 mM) ( Fig. 4a) to treat a panel of T-ALL cell lines. GSKJ4 significantly affected the growth of human T-ALL cell lines and primary human T-ALL cells (T-ALL1-3), leading to cell cycle arrest and increased apoptosis compared with control-inhibitor-treated cells ( Fig. 4b and Extended Data Fig. 8a-h ). The first detectable changes started at 24 h, and we observed significantly altered phenotypes at 48 h and 72 h (Extended Data Fig. 8i ). These GSKJ4 effects appear to be connected to the demethylase activity of JMJD3, as overexpression of catalytically inactive JMJD3 did not rescue the phenotype (Extended Data Fig. 8j , k). The growth of myeloid leukaemia cells, stromal cells and haematopoietic progenitor cells (Extended Data Fig. 8l , m) was unaffected by GSKJ4, demonstrating specificity of function. Mechanistically, we detected gene expression changes starting at 24 h post-GSKJ4 treatment, and significant changes were noted at 48 h and 72 h (Extended Data Fig. 8n ) and were coupled to an increase in the H3K27me3 levels at repressed genes (Extended Data Fig. 9a -c). The NOTCH1 and JMJD3 occupancy at specific NOTCH1 target genes that were tested, as well as the total cellular levels of NOTCH1 and JMJD3 and the chromatin H3K27me3 levels, did not significantly change over the treatment duration (Extended Data Fig. 9a-e ).
Genome-wide studies identified 486 downregulated genes after 72 h of treatment of human T-ALL cells (CUTLL1) with GSKJ4 ( Fig. 4c ). There was a significant overlap between the shJMJD3 and GSKJ4 signatures for both downregulated genes (P 5 4.88 3 10 244 ; Fig. 4d and Supplementary Table 3 ) and upregulated genes (P 5 2.57 3 10 220 ). By contrast, the shUTX-upregulated gene signature significantly overlapped with the GSKJ4-downregulated gene signature. Furthermore, there was a significant overlap between genes upregulated in Utx knockout blasts and downregulated by GSKJ4 treatment (P 5 2.49 3 10 29 ; Figs 3e and 4d and Supplementary Table 3 ), suggesting again that UTX and JMJD3 play opposing roles in T-ALL. Genome-wide study of H3K27me3 localization demonstrated that the GSKJ4-downregulated genes experienced gain of H3K27me3 upon GSKJ4 treatment and were marked by the presence of H3K4me3, NOTCH1 and JMJD3 at their promoters ( Fig. 4c and Extended Data Fig. 1j ). Well-characterized NOTCH1 and JMDJ3 targets are highlighted as representative examples of the GSKJ4-downregulated/ shJMJD3-downregulated signature and show a significant gain in H3 K27me3 upon GSKJ4 treatment ( Fig. 4e and Extended Data Fig. 9f ). UTX was not involved in the regulation of the oncogenic NOTCH1 targets, as revealed by ChIP studies (Extended Data Fig. 9g ).
We propose targeting JMJD3 as a novel therapeutic option for paediatric and adult T-ALL. This proposal is based on recent studies 2 
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a key role in T-ALL, through antagonism with oncogenic NOTCH1. We demonstrate here that NOTCH1-mediated recruitment of JMJD3 to promoters can explain this antagonism (Extended Data Fig. 10 and see also Supplementary Discussion for extended discussion). We propose that NOTCH1 recruitment leads to PRC2 eviction as a result of the active demethylation of H3K27 through the catalytic activity of JMJD3 and the recruitment of JMJD3 to target promoters. By contrast, the reported increases in the levels of the activating H3K4me3 mark on a large fraction of NOTCH1 target genes 27 (Fig. 4c) can be explained by the fact that NOTCH1 has the ability to participate in MLL complexes (Extended Data Figs 2 and 10) . Moreover, we demonstrate the anti-tumorigenic activities of the inhibitor GSKJ4 (ref. 5) and its specificity for T-ALL cells. Clearly, we cannot exclude the possibility that GSKJ4 affects other important epigenetic modulators or signalling pathways. Nevertheless, we consider that the main action of this inhibitor in T-ALL is channelled through the inhibition of JMJD3 activity and propose that such compounds should be tested either as single drugs or in combination with standard chemotherapy. 
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METHODS
Mice, cell culture and primary cell samples. The Jmjd3 (ref. 29 ) and Utx 28 knockout mouse models, as well as the corresponding genotyping strategy, have been described previously. All animals used in this study were treated according to IACUC protocols for the laboratories of I.A., A.A.F. and R.J. The human T-ALL cell lines CUTLL1 (ref. 30 ), P12-Ichikawa, Loucy, DND41, CEM and Jurkat and the myeloid leukaemia cell lines (THP-1 and HL-60), as well as the mouse T-ALL line (720) 31 , were cultured in RPMI 1640 medium supplemented with 20% FBS and penicillin and streptomycin. All cell lines were tested for the presence of mycoplasma, and only mycoplasma-free lines were used for these studies. Primary human samples were collected by collaborating institutions with informed consent and were analysed under the supervision of the Columbia University Medical Center and St. Jude Children's Research Hospital Institutional Review Boards. The primary cells treated with GSKJ4 inhibitor (for more information on these cells, see ref. 32 ) were cultured in MEMa medium plus 10% FBS (StemCell Technologies, #06400), 10% human AB 1 serum (Invitrogen), 1% penicillin/streptomycin, 1% GlutaMAX, human interleukin-7 (IL-7) (R&D Systems; 10 ng ml 21 ), human Flt3 ligand (Peprotech; 20 ng ml 21 ), human SCF (Peprotech; 50 ng ml 21 ) and insulin (Sigma; 20 nmol l 21 ). Irradiated MS5 stromal cells overexpressing delta-like 1 (DLL1) were used as a feeder layer, as previously described 33 .
In vitro drug treatment and shRNA treatment and cell growth, apoptosis and cell cycle analysis. T-ALL cells were infected twice with shRNA-expressing retroviruses and selected using puromycin. Expression studies took place at different time points during the selection period, and we present the results from day 4 during selection. To calculate the IC 50 of GSKJ4 (GlaxoSmithKline) 5 normalized to the control inhibitor GSKJ5 (GlaxoSmithKline), T-ALL lines were treated with different concentrations of the drug for 5 days. For cell growth, cell lines and primary cultures were treated with 2 mM GSKJ4 and GSKJ5 for various times (24 h to 72 h) and stained with annexin V and subjected to cell cycle analysis. c-Secretase inhibitor (cSI, specifically Compound E (Alexis Biochemicals)) was used at 500 nM for various periods. For the cell cycle analysis, 5-bromodeoxyuridine (BrdU;10 mM) was added for a 1 h pulse, and incorporation into DNA was determined by using the BrdU Flow Kit (BD Biosciences). Apoptosis was studied by quantification of annexin V staining using the BD Biosciences kit and flow cytometry according to standard protocols provided by the manufacturer. Doxycycline was used at 1 mg ml 21 final concentration.
Intravenous and subcutaneous xenograft studies. Studies were conducted as previously published 4 . In both cases, CUTLL1, P12 or CEM T-ALL cells expressing luciferase (FUW-LUC) and the corresponding shRNA (shJMJD3, shUTX or shRenilla) were used. For the intravenous studies, 1 3 10 6 cells were injected retroorbitally into sublethally irradiated female NRG (NOD Rag1 2/2 Il2rg 2/2 ) mice. For subcutaneous studies, 1 3 10 6 cells were mixed with an equal volume of BD Matrigel basement membrane and injected into the flanks of female NOD-SCID mice. In both cases, cell growth was monitored every 2 days using IVIS (Caliper, PerkinElmer). Transplantation for reconstitution of the haematopoietic system and for disease progression analysis. Fetal livers from Jmjd3 1/1 , Jmjd3 1/2 and Jmjd3 2/2 embryos (E13.5, Ly45.2 background) were provided by S.A.'s laboratory, and 1 3 10 6 total (unfractionated) fetal liver cells were used for the reconstitution of the haematopoietic system of lethally irradiated recipients on a Ly45.1 background. Bone marrow was isolated from the recipients, followed by isolation of cells of the Ly45.2 background using flow cytometry. Total Ly45.2 bone marrow mononuclear cells (2.5 3 10 5 cells) were mixed with equal numbers of Ly45.1 (wild-type) bone marrow cells and transplanted into lethally irradiated recipients to study haematopoietic reconstitution in a competitive setting. For the Utx 1/1 , Utx 1/2 and Utx 2/Y (Ly45.2) background, 2.5 3 10 5 cells of total Ly45.2 bone marrow mononuclear cells were mixed with equal numbers of Ly45.1 (wild-type) bone marrow cells and transplanted into lethally irradiated recipients to study haematopoietic reconstitution in a competitive setting similar to the Jmjd3 study.
In both cases, reconstitution of the haematopoietic system was monitored by analysis of the peripheral blood for the main haematopoietic lineages. The thymus and spleen of some recipients were isolated and analysed at 3 months post transplantation.
For analysis of leukaemia progression, c-Kit 1 haematopoietic progenitors from the bone marrow of both Jmjd3 and Utx knockout models were magnetically selected (STEMCELL Technologies) using an antibody against CD117 (c-Kit) and were cultured overnight in the presence of 50 ng ml 21 SCF, 50 ng ml 21 Flt3 ligand, 10 ng ml 21 IL-3 and 10 ng ml 21 IL-6. Overexpression of oncogenic Notch1 mutants (the intracellular part of NOTCH1 (NOTCH1-IC) and DeltaE (NOTCH1-DE)) in bone marrow haematopoietic progenitors followed by transplantation into mouse recipients led to the development of T-ALL, characterized by the presence of leukaemic blasts in the peripheral blood that infiltrated the peripheral lymphoid organs, progressively leading to the death of the animals (Extended Data Fig. 5c ). The cells were infected with NOTCH1-IC or NOTCH1-DE (and green fluorescent protein (GFP)) expressing retroviruses twice (24 h and 48 h post c-Kit selection). Viral transduction efficiency was determined by measuring reporter fluorescence over a total period of 4 days, and total populations were transferred via retro-orbital injection into lethally irradiated congenic recipients along with 2.5 3 10 5 total (wild-type) bone marrow mononuclear cells for haemogenic support. GFP 1 cells (4 3 10 4 ) were transplanted in both NOTCH1-IC and NOTCH1-DE studies. The Mantel-Cox test was used for the analysis of the survival data. No randomization or blinding method was used during these animal studies. Antibodies, reagents, kits and virus production. Protein-G-coated magnetic beads were purchased from Invitrogen. Antibodies against the following proteins were used: monoclonal mouse H3K27me3 (histone H3 migrates at around 17 kDa) (Abcam, ab6002), monoclonal mouse H3K27me1 (Active Motif, 61015), polyclonal rabbit H3K4me3 (Active Motif, 39159), polyclonal rabbit NOTCH1 (the intracellular part of the protein migrates at around 110 kDa), polyclonal rabbit JMJD3 (protein migrates at around 170 kDa) (Abgent, AP1022a (human) and AP1022b (mouse)), as well as polyclonal rabbit JMJD3 (Cell Signaling Technology, 3457), polyclonal rabbit UTX (protein migrates at around 160 kDa) (Abcam, ab36938, and Bethyl Laboratories, A302-374A), polyclonal rabbit NF-kB (p65, protein migrates at around 65 kDa) (Santa Cruz Biotechnology, sc-109 and sc-372) and control IgG (Santa Cruz Biotechnology, msc-2025 (mouse) and sc-2027 (rabbit)). All antibodies for flow cytometry were from eBioscience. All antibodies used had been tested and shown to be specific for the purposes we used them for by the suppliers. The acid extraction protocol by Abcam was used for the characterization of histone mark levels upon GSKJ4 treatment. To generate the virus, we infected 293T cells with a plasmid expressing the shRNA (an miR-30-based system 34 ) against JMJD3 or UTX (shJMJD3A, 59-CAGGGAAGTTTCGAGAAGTCCTATAGTGAAGCCACAGATGTATAGG ACTCTCGAACTTCCCTT-39; shJMJD3B, 59-ACACCAGCAGTAGCAACAGC AATAGTGAAGCCACAGATGTATTGCTGTTGCTACTGCTGGTGG-39; shUTX, 59-ACACAAGGTAGTCTACAGAATATAGTGAAGCCACAGATGTATATTC TGTAGACTACCTTGTGG39). We also used shRenilla (59-CTCGAGAAGGTA TATTGCTGTTGACAGTGAGCGCAGGAATTATAATGCTTATCTATAGTG AAGCCACAGATGTATAGATAAGCATTATAATTCCTATGCCTACTGCCT CGGAATTC-39) as a control and the retroviral packaging plasmid. Viral supernatant was collected over a period of 72 h and used for the transduction of T-ALL cells. The cells were infected twice and then selected with puromycin starting 3 days after viral infection. Reporter fluorescence was used (as determined by flow cytometry) for the quantification of shRNA. Histopathology. Organs were harvested from the animals and immersion fixed with 4% paraformaldehyde 4 overnight at 4 uC. Samples were washed with PBS three times for 1 h at room temperature and dehydrated in 70% ethanol. Samples were embedded in paraffin blocks. Sections (6-mm thick) were stained with haematoxylin and eosin following standard procedures. Peripheral blood smears were briefly fixed in methanol and stained with Wright-Giemsa solution (Fisher). Slides were rinsed with water, dried, mounted with Cytoseal 60 and coverslipped. Protein immunoprecipitation for interaction studies. For the interaction studies between the NOTCH1 complex (NOTCH1 and MAML1) and the epigenetic modulators (UTX, JMJD3 and EZH2), we used standard protocols used elsewhere.
In brief, cells were resuspended in TENT buffer (50 mM Tris, pH 8.0, 5 mM EDTA, 150 mM NaCl and 0.05% (v/v) Tween-20) supplemented with the inhibitors at a concentration of 20 3 10 6 cells ml 21 buffer. Cell lysates were passed through a 25G syringe five times and incubated on ice for 30 min, followed by centrifugation to remove cell debris (5 min, 13,000g). The cleared lysate was precleared with beads for 1 h at 4 uC to decrease non-specific binding and incubated overnight with the corresponding antibody-bound bead complexes. Five micrograms of antibody was used for 3 mg of extracts. RNA-seq library preparation and analysis. Whole RNA was extracted from 1-5 3 10 6 T-ALL cells or primary cells using the RNeasy kit (QIAGEN) according to the manufacturer's protocol. Poly(A) 1 RNA was enriched using magnetic oligo(dT)containing beads (Invitrogen). cDNA was prepared and strand-specific libraries were constructed using the dUTP method as described previously 35 . Libraries were sequenced on the Illumina HiSeq 2000 using the 50-base-pair single-read method. ChIP and ChIP-seq library preparation. ChIP experiments were performed as described previously 4 . In brief, for the analysis of histone marks, we fixed the cells with 1% formaldehyde for 10 min at 25 uC and lysed them by the addition of nucleus incubation buffer (15 mM Tris, pH 7.5, 60 mM KCl, 150 mM NaCl, 15 mM MgCl 2 , 1 mM CaCl 2 , 250 mM sucrose and 0.3% NP-40) and incubation at 4 uC for 10 min. The nuclei were washed once with digest buffer (10 mM NaCl, 10 mM Tris, pH 7.5, 3 mM MgCl 2 and 1 mM CaCl 2 ), and we used micrococcal nuclease (USB) in digest buffer to generate mononucleosomal particles. The reaction was stopped by the addition of EDTA (20 mM). The nuclei were lysed in nucleus lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, pH 8.0, and 1% SDS) followed by sonication using a Bioruptor (Diagenode), and chromatin was precleared by the addition of nine RESEARCH LETTER volumes of IP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, pH 8.0, 16.7 mM Tris-HCl, pH 8.0, and 167 mM NaCl) and magnetic Dynabeads. One per cent of the chromatin was kept as input. We coupled 2.5 mg antibody with 25 ml of beads for 4 h in reaction buffer, and the complex was added to precleared chromatin (the equivalent of 10 5 -10 6 cells, depending on the antibody) followed by overnight incubation at 4 uC with rotation. We washed the complexes bound to the beads using buffers with increasing salt concentration: once with wash A (20 mM Tris-HCl, pH 8, 150 mM NaCl, 2 mM EDTA, 1% (w/v) Triton X-100 and 0.1% (w/v) SDS), once with wash B (20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 2 mM EDTA, 1% (w/v) Triton X-100 and 0.1% (w/v) SDS), once with wash C (10 mM Tris-HCl, pH 8.0, 250 mM LiCl, 1 mM EDTA, 1% (w/v) NP-40 and 1% (w/v) deoxycholic acid) and twice with TE, followed by treatment with RNase and proteinase K. The crosslinks were then reversed, and the DNA was precipitated using ethanol and glycogen.
For JMJD3 ChIP, the cells were fixed with 1% formaldehyde for 10 min at 25 uC and lysed on ice using 1 ml cell lysis buffer (50 mM HEPES-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40 and 0.25% Triton X-100) per 1 3 10 7 cells. We resuspended the pellet in 1 ml buffer II (10 mM Tris-HCl, pH 8, 200 mM NaCl, 1 mM EDTA, pH 8, and 0.5 mM EGTA) per 1 3 10 7 cells. We further resuspended the nuclei in buffer III (10 mM Tris-HCl, pH 8, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium deoxycholate and 0.5% n-lauroylsarcosine) and sonicated the solution with a Bioruptor for 40 min. Triton X-100 was added to a final concentration of 1%, and the chromatin preparation was precleared using magnetic beads. The antibody (5 mg) was coupled to the magnetic beads (50 ml) as in the case of the histone marks, and the complex was added to the precleared chromatin (the equivalent of 1 3 10 7 cells per reaction). The reaction mix was then incubated for 12-16 h. The beads with the immunoprecipitated chromatin fragments were washed eight times with RIPA buffer (50 mM HEPES-KOH, pH 7.6, 300 mM LiCl, 1 mM EDTA, 1% NP-40 (IGEPAL) and 0.7% sodium deoxycholate) and once with TE. The DNA was cleaned as in the case of the chromatin marks (see above). Libraries were generated as described previously 4 , including end repair, A-tailing, adaptor ligation (Illumina TruSeq system) and PCR amplification of the libraries. AMPure XP beads (Beckman Coulter, A63880) were used for DNA cleaning in each step of the process. Sequence analysis of primary samples. Sequencing and analysis of paediatric T-ALL samples was conducted as described in previously published studies 2, 36 . In brief, sequencing of UTX in the paediatric T-ALL cohort was performed by PCR of whole genome amplified DNA, followed by sequencing using 3730xl instruments (Applied Biosystems) as previously described 37 . Single nucleotide variations were detected by SNPdetector 38 and PolyScan 39 and validated by sequencing of both tumour and matched non-tumour samples. A total of 107 paediatric patients were screened, including 64 cases with ETP ALL (25 females and 39 males) and 43 with 'typical' T-ALL (8 females and 35 males). UTX mutations were detected in 4.7% of the total population and in 6.8% of the male population. No UTX mutations were detected in female samples. The two deletions and one of the frameshift mutations were found in patients with typical T-ALL, and the other two in patients with ETP ALL.
Regarding the adult T-ALL case, all 83 samples were collected in the Eastern Cooperative Oncology Group (ECOG) clinical trials E2993 (ref. 40 ) and C10403 and analysed under the supervision of the Columbia University Medical Center Institutional Review Board. Informed consent to use leftover material for research purposes was obtained from all of the patients at trial entry in accordance with the Declaration of Helsinki. All exon sequences from UTX were amplified from genomic DNA by PCR and analysed by direct dideoxynucleotide sequencing. The primer sequences used for UTX sequencing have been described previously 20 . Data sources and computational tools. Patient and physiological T-cell expression data were obtained from refs 2, 24, 41. Human genome assembly version hg19/ GRCh37 and Ensembl annotation release 69 were used for the RNA-seq, ChIP-seq and data integration analyses. NOTCH1, RBP-J, H3K4me3 and H3K27me3 ChIPseq data for CUTLL1 cells were obtained from ref. 27 . For the functional enrichment analysis, MSigDB 42 version 3.1 was used. Bowtie 43 version 0.12.7 was used for alignment of sequenced reads. RNA-seq data analysis was performed using DEGseq 44 . MACS 45 version 2.0.10 was used for JMJD3 ChIP-seq peak discovery, in conjunction with the irreproducible discovery rate (IDR) method 46 Fig. 1e ). A gene was considered significantly overexpressed in T-ALL compared with the rest of the sample categories if at least one of its associated probes was significantly overexpressed in T-ALL according to the statistical test.
Genes experiencing loss of H3K27me3 at TSSs in our mouse NOTCH-IC model compared with normal double-positive (DP) mouse cells were obtained from our previous study 4 . Enrichment of human homologues of these genes in JMJD3-correlating genes in the patient data described above was estimated as follows. First, Pearson's correlation of JMJD3 expression (separately for each JMJD3 probe) against expression of each gene was computed. Then, the distribution of the correlations of the genes losing H3K27me3 (human homologues of the mouse genes) was compared with that of the genes that did not lose H3K27me3, using Student's t-test (separately for each JMJD3 probe, minimum P value shown in the corresponding figure (Fig. 1f) ) or the Wilcoxon one-sided unpaired test (data not shown), yielding similar results. This analysis was repeated for NF-kB1, NF-kB2, REL, RELA, RELB, HES1, UTX and EZH2 (Extended Data Fig. 1i ). JMJD3 peak identification, characterization and overlap with published data sets. JMJD3 ChIP-seq reads were aligned using Bowtie (with default parameters, except for -m 1 so as to report only unique alignments) on human assembly version hg19. Peak discovery was performed with MACS (version 2.0.10) using default parameters, except for using a fragment size of 300 base pairs as estimated with the Agilent 2100 Bioanalyzer. Sonicated input was used as a control for peak discovery. Then, we used the IDR method 46 , guidelines and pipeline available for narrow peaks at the URL https://sites.google.com/site/anshulkundaje/projects/idr to determine highly reproducible peaks supported by both JMJD3 replicates.
JMJD3 peaks were characterized according to their genome-wide distribution (Extended Data Fig. 1k ) into the following groups: (a) 1-kilobase (kb) TSS-flanking regions of transcript isoforms; (b) gene body regions (excluding any regions overlapping with (a)); and (c) upstream regions of a minimum of 10 kb and a maximum of 100 kb (excluding any regions overlapping with (a) or (b)).
Co-occurrence of JMJD3 peaks with H3K4me3, H3K27me3, NOTCH1 and RBP-J was computed as the percentage of such peaks (5,000 top-scoring peaks for each protein obtained from ref. 27 ; GEO accession GSE29600) that have some overlap with a JMJD3 peak. The statistical significance of these overlaps was determined using random resampling simulation (for example, H3K4me3 peaks were randomly redistributed along the genome). As a control, we used the percentage of TSSs that have JMJD3 peaks (this is a rather conservative control since genome-wide JMJD3 occupancy is much lower, as a result of JMJD3 being concentrated in TSSs), and compared with this control, we obtained an ,7-fold enrichment of H3K4me3-JMJD3 (P , 0.001 as determined by the random resampling scheme). Similar enrichments were obtained for NOTCH1-JMJD3 and RBP-J-JMJD3 co-occurrence, whereas no significant enrichment was observed for H3K27me3-silenced or H3K4 me1 enhancer-related regions (Extended Data Fig. 1j ). RNA-seq analysis. Differential gene expression analysis was performed for each matched knockdown versus control pair, separately in each biological or technical replicate in each of two cell lines (CUTLL1 and CEM). Three types of comparisons were tested: (1) JMJD3 knockdown versus Renilla; (2) JMJD3 knockdown versus UTX knockdown; and (3) UTX knockdown versus Renilla. DEGseq 44 was used to analyse (a) matched knockdown-Renilla replicates in separate DEGseq runs and (b) all replicates on a combined DEGexp run. For the mouse (Utx knockout) samples, spleen and bone marrow from a wild-type male (referred to as animal #9), as well as spleen from a wild-type female (animal #10), were compared with spleen and bone marrow from a knockout male (#23) and spleen from another knockout male (#27) (see also our GEO accession GSE56696). For illustration, scatter plots ( Fig. 2d and Extended Data Fig. 3g -i) were created using values obtained from DEGseq analysis of merged biological and/or technical replicates. Gene RNA-seq FPKM values were computed using GenomicTools 47 . The P-value cutoff for differential expression was set at 1 3 10 25 , with the minimum absolute log 2 fold change set at 0.5. However, all key results in this study (that is, the significance of the overlaps of the various gene expression signatures demonstrating the contrasting roles of JMJD3 and UTX) are robust to changes in these two parameters (data not shown).
The P value of a gene set of size t (for example, GSKJ4-downregulated genes) containing k genes with a specific attribute (for example, shJMJD3-mediated downregulation or UTX knockout upregulation) was determined against the null hypothesis that k or more such genes could have been observed merely by chance in an equal sized gene set that was randomly drawn from the entire reference set of genes of size N (that is, all downregulated, upregulated and constant genes). This P value was obtained by using the hypergeometric cumulative distribution with parameters N, t, k and n, where n is the number of genes possessing the attribute in the entire reference gene set of size N. H3K27me3 gain and loss analysis. JMJD3-affected (upregulated or downregulated) genes were defined as genes whose expression was significantly differentially expressed in JMJD3 knockdown cells compared with both Renilla and UTX knockdown cells. Changes in JMJD3 binding and the H3K27me3 mark around gene
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TSSs between cells treated with the inhibitor GSKJ4 and the control GSKJ5 were determined using GenomicTools (''genomic_apps peakdiff'' tool) as described in a previously published study 4 . Epigenetic changes between the treatment (shJMJD3 or GSKJ4) and control samples were determined by evaluating sliding windows across the genome using the following protocol. First, enriched ChIP-seq windows were identified separately for each of the two samples under comparison using a window-based approach and the binomial probability distribution to compare signal reads with control reads in each window. Subsequently, for each genomic window enriched in at least one of the two samples, the total number of reads was determined, and the window read counts were normalized using quantile normalization across biological replicates and samples before comparison. Finally, for each window, the fold change between the two samples was calculated (GSKJ4 versus control, and vice versa). To estimate the false discovery rate, the distribution of the observed H3K27me3 fold changes was compared with the distribution of fold changes between replicates of the same treatment. This comparison was performed independently at different H3K27me3 read density levels to control for artificially high fold changes due to low read counts in the denominator. Significant epigenetic changes are reported at 5% false discovery.
JMJD3, NOTCH1, H3K4me3 and H3K27me3 heatmaps were generated using GenomicTools (''genomic_apps heatmap'' utility) over log-transformed read counts in 200-nucleotide non-overlapping bins of 4-kb-flanked TSSs. Box plots of H3K27 me3 log 2 [fold changes] (GSKJ4 versus control) show the distribution of values in (a) JMJD3 targets, (b) commonly downregulated genes upon shJMJD3 and GSKJ4 treatment, and (c) the intersection of GSKJ4-upregulated and shJMJD3-upregulated genes as a negative control. P values were computed using a one-sided Wilcoxon unpaired test for (a) and (b) versus the control (c). RNA-seq and ChIP-seq replicate reproducibility. For RNA-seq experiments, we focused on the reproducibility of gene expression levels as measured by FPKM values. For each pair of replicates, we computed the Spearman and Pearson correlations, as well as the Pearson correlation on log-transformed FPKM values. In general, Pearson correlations were much higher because higher values are dominant, and highly expressed genes tend to be more reproducible. Using a Pearson correlation on logtransformed values attempts to balance the expression distribution and allow contributions from genes that are expressed at a lower level, thereby providing a more realistic genome-wide reproducibility metric. Spearman correlations focus on the ranking of gene expression, and in our experiments, in general, were a more conservative (that is, lower) and consistent (lower variability across various settings, and when comparing different cell lines (that is, CUTLL1 and CEM)) estimate of reproducibility; therefore, for simplicity, we have reported only the Spearman correlations.
For ChIP-seq 'broad peak' experiments (H3K27me3), we also used Pearson, logtransformed Pearson and Spearman correlations on (a) TSSs and (b) all genome-wide peaks. As before, Spearman correlation was the most conservative and consistent estimate of reproducibility.
For ChIP-seq 'narrow peak' experiments (JMJD3), in addition to TSS-based and genome-based correlations, we used the IDR method 46 , guidelines and pipeline available for narrow peaks at the URL https://sites.google.com/site/anshulkundaje/ projects/idr. Apart from determining the reproducibility, we also used the IDR method to determine high-confidence peaks supported by both JMJD3 replicates. Figure 2 | JMJD3 is vital for T-ALL growth through participation in NOTCH1 transcriptional programs. a, NOTCH1 interaction analyses for JMJD3, MAML1 and WDR5 proteins in 293T cells. Interaction with JMJD3 was confirmed in a reciprocal way (right-most lane, immunoprecipitation (IP) using an anti-haemagglutinin (HA) antibody). b, Expression of JMJD3 and WDR5 in 293T cells, followed by immunoprecipitation using the anti-HA antibody against HA-JMJD3. An anti-Flag antibody was used for the detection of both proteins. c, NOTCH1 interaction studies for JMJD3 and MAML1 proteins in mouse T-ALL cells expressing a Flag/Strep form of intracellular NOTCH1. StrepTactin beads were used for NOTCH1 precipitation in the absence of detectable intracellular NOTCH1, and different antibodies were used for the detection of JMJD3, MAML1, EZH2 and UTX. Extracts from green fluorescent protein (GFP)expressing cells were used as negative control. All experiments were repeated three times (biological replicates), and a representative example is shown. d, mRNA expression of JMJD3 and UTX upon treatment with shRNA against JMJD3 or UTX. The expression after treatment of CEM cells with two shRNAs against JMJD3 and one shRNA against UTX and one control (Renilla) is shown. e, The effects on cell proliferation as measured by the loss of GFP-expressing shRNA. HL-60 is an acute promyelocytic leukaemia cell line (APL), which is a subtype of acute myeloid leukaemia (AML) and is used as control in this study. For both cell lines, the average results from three representative studies are shown. f, Annexin V staining upon shJMJD3 and shRenilla treatment of CUTLL1 cells (top) and HPB-ALL cells (bottom).
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Extended Data Figure 4 | In vivo studies of the role of JMJD3 in T-ALL using luciferase analysis of CEM-, P12-and CUTLL1-based xenograft models in immunocompromised (NRG) mouse recipients. a, b, In vivo growth of CEM T-ALL cells in subcutaneous xenograft studies upon genomic ablation of JMJD3 and UTX (red and green circles denote shJMJD3-expressing cells (two different shRNAs); blue denotes shUTX-expressing cells; and black circles denote shRenilla-expressing cells). One million CEM cells were injected into the animals, and representative graphs from five mouse recipients and an image of a representative mouse on days 0 and 6 are shown (a). Representative graphs from five mouse recipients and the average luciferase intensity on days 0 and 6 are shown (b). c, Results for growth of CEM cells at different time points post transplantation in subcutaneous xenograft studies (n 5 5). d, Comparison of in vivo cell growth in the subcutaneous model of shJMJD3-, shUTX-and shRenilla-expressing P12 cells (n 5 5).
One million P12 cells were injected into sublethally irradiated NRG (immunocompromised) recipients, and the mice were monitored every day for luciferase activity. Day 0 was the first day that a substantially detectable luciferase intensity was measured. The last day of the experiment was the day that either luciferase intensity reached saturation or the mice were euthanized for humanitarian reasons. Red and green circles denote shJMJD3expressing cells (two different shRNAs, shJMJD3A and shJMJD3B); blue denotes shUTX-expressing cells; and black circles denote shRenilla-expressing cells. e, Monitoring the change in luciferase intensity over a period of seven days in the subcutaneous xenograft model using CUTLL1 T-ALL cells (n 5 4). f, g, Intravenous xenograft studies using CUTLL1 cells injected into sublethally irradiated NRG (immunocompromised) recipients (n 5 8 or 6, as indicated in the figure) . In e-g, 0.5 310 6 CUTLL1 cells were transplanted, and the mice were monitored every day for luciferase activity.
